Using the newest technologies for sequencing DNA, the project’s nine centers sequenced the complete genome of 179 people and the protein-coding genes of 697 people. Each region was sequenced several times, so that a lot more than 4.5 terabases of DNA sequence had been collected. A consortium including academic centers on multiple continents and technology companies that developed and sell the sequencing tools completed the work. To procedure these data necessary many computational and technical innovations, including standardized methods to organize, store, discuss and analyze DNA sequencing data. Released in 2008, the 1000 Genomes Project began with three pilot tasks to develop, evaluate and compare approaches for creating a catalogue of genetic variations.Moreover, it demonstrates AMT’s development capability. A future approval of the MAA for Glybera would completely validate our gene therapy approach and our adeno-linked viral vector delivery platform. We believe this task offers desire to many patients, as gene therapy may become the therapeutic strategy of choice for inherited disorders’ stated Jorn Aldag, CEO of AMT. The EMA formal review will become carried out via the centralised process, which is the standard route for all advanced therapies. During 2010, AMT expects to provide further updates on the total results from its follow-up and ongoing studies, in accordance with reporting regulations.